Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer

A Phase II study of the safety, pharmacokinetics and efficacy of IncelTM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC)

European Journal of Cancer ◽

10.1016/s0959-8049(99)81827-9 ◽

1999 ◽

Vol 35 ◽

pp. S349 ◽

Cited By ~ 1

Author(s):

A. Einstein ◽

R. Lush ◽

R. Rago ◽

G. Bubley ◽

W.D. Henner ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

European Urology ◽

10.1016/j.eururo.2007.02.060 ◽

2007 ◽

Vol 52 (4) ◽

pp. 1020-1027 ◽

Cited By ~ 13

Author(s):

Giuseppe Di Lorenzo ◽

Riccardo Autorino ◽

Sisto Perdonà ◽

Michele De Laurentiis ◽

Massimo D'Armiento ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Hormone Refractory ◽

First Line Treatment

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study

Cancer ◽

10.1002/1097-0142(19930915)72:6<1965::aid-cncr2820720629>3.0.co;2-x ◽

1993 ◽

Vol 72 (6) ◽

pp. 1965-1968 ◽

Cited By ~ 26

Author(s):

Timothy M. Kuzel ◽

Martin S. Tallman ◽

Daniel Shevrin ◽

Edward Braud ◽

Lary Kilton ◽

...

Keyword(s):

Prostate Cancer ◽

Continuous Infusion ◽

Phase Ii ◽

Phase Ii Study ◽

Cancer Center ◽

Hormone Refractory ◽

Center Study

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

Investigational New Drugs ◽

10.1023/b:drug.0000047109.76766.84 ◽

2005 ◽

Vol 23 (1) ◽

pp. 79-84 ◽

Cited By ~ 51

Author(s):

Tahir Latif ◽

Laura Wood ◽

Cindy Connell ◽

David C. Smith ◽

David Vaughn ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Phase II Study of Vinorelbine and Low-Dose Docetaxel in Chemotherapy-Naive Patients with Hormone-Refractory Prostate Cancer

The Cancer Journal ◽

10.1097/00130404-200307000-00011 ◽

2003 ◽

Vol 9 (4) ◽

pp. 286-292 ◽

Cited By ~ 14

Author(s):

Alan J. Koletsky ◽

Manuel L. Guerra ◽

Lori Kronish

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Study ◽

Phase II study of vlnorelbine in patients with hormone refractory prostate cancer

European Journal of Cancer ◽

10.1016/s0959-8049(97)84523-6 ◽

1997 ◽

Vol 33 ◽

pp. S33

Author(s):

A. Caty ◽

S. Oudard ◽

Y. Humblet ◽

M. Beauduin ◽

E. Suc ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

899 PUBLICATION A phase II study of sequential chemotherapy with docetaxel-estramustine phosphate (DE) followed by mitoxantrone-prednisone (MP) in patients (pts.) with metastatic hormone refractory prostate cancer (MHRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81194-2 ◽

2005 ◽

Vol 3 (2) ◽

pp. 258

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Estramustine Phosphate ◽

Sequential Chemotherapy ◽

A phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.4725 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 4725-4725 ◽

Cited By ~ 1

Author(s):

B. Mellado ◽

A. Font ◽

J. Carles ◽

G. Catalán ◽

J. L. González Larriba ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Weekly Docetaxel ◽

Combination of estramustine, paclitaxel, and tegafur-uracil (ETU) in patients with metastatic hormone-refractory prostate cancer (mHRPC): Efficacy and safety results of a multicenter phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.16027 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 16027-16027

Author(s):

O. Fitoussi ◽

F. Guichard ◽

S. Hirt ◽

N. Dohollou ◽

C. Bureau ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Multicenter Phase ◽

A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.5166 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5166-5166 ◽

Cited By ~ 6

Author(s):

K. N. Chi ◽

E. K. Beardsley ◽

P. M. Venner ◽

B. J. Eigl ◽

S. J. Hotte ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽